Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,708.60
Bid: 1,708.40
Ask: 1,708.80
Change: 0.00 (0.00%)
Spread: 0.40 (0.023%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,708.60
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

12 Sep 2014 15:13

First person in UK trial to get experimental Ebola shot next week

By Kate Kelland LONDON, Sept 12 (Reuters) - The first human volunteer in a fast-tracked British safety trial of an experimental vaccine to fight Ebola is to be injected with the shot next week, organisers of the trial said on Friday. The candidate Ebola vaccine is being co-developed b

Read more
12 Sep 2014 10:17

INSIGHT-As Big Tobacco takes up e-cigarettes, investors look ahead

* Sector not as attractive for private funds as it once was * NJOY piques interest of Big Tobacco and Pharma-sources * Gamucci close to fund raising, new product launch-CEO * BAT says nicotine inhaler licensed as medical product By Martinne Geller and Jilian Mincer L

Read more
11 Sep 2014 08:35

UK BROKER RATINGS: Credit Suisse Upgrades TUI Travel To Outperform

Read more
9 Sep 2014 13:57

Glaxo In Collaboration With UK And South African Research Councils

Read more
9 Sep 2014 10:55

PRESS: Glaxo's China Unit Was Investigated In US Probe - Reuters

Read more
8 Sep 2014 15:41

Broker tips: Glaxosmithkline, AB Foods, De La Rue

Credit Suisse has slashed its earnings forecasts for Glaxosmithkline (GSK) before an expected restatement of divisional reporting at the pharmaceutical group. The bank has trimmed its target price for the stock from 1,475p to 1,400p and maintained an 'underperform' rating. It said that GSK's shares

Read more
8 Sep 2014 14:46

UPDATE 1-Cost a focus as GSK takes lead in new wave of biotech lung drugs

* GSK drug ahead of similar ones from Teva and AstraZeneca * Under-the-skin injection set for filing this year * NEJM editorial questions cost-effectiveness of new drugs * Analysts see fragmented market for biotech lung treatments (Adds more detail on Teva drug, analyst commen

Read more
8 Sep 2014 13:29

Glaxo Ambrisentan/Tadalafil Late Stage Study Meets Primary Endpoint

Read more
8 Sep 2014 12:58

Glaxo Notes Positive Phase III Data For Asthma Treatment Mepolizumab

Read more
8 Sep 2014 12:45

Cost a focus as GSK takes lead in new wave of biotech lung drugs

* GSK drug ahead of similar ones from Teva and AstraZeneca * Under-the-skin injection set for filing this year * Data on GSK's mepolizumab presented at Munich congress * NEJM editorial questions cost-effectiveness of new drugs By Ben Hirschler LONDON, Sept 8 (Reuters

Read more
8 Sep 2014 11:36

London midday: UK stocks sink on fears over Scottish referendum, Ukraine

Concerns surrounding the upcoming referendum on Scottish independence and a fragile ceasefire agreement in Ukraine were weighing heavily on UK stocks on Monday. London's FTSE 100 was trading down 1% at 6,789 by midday. The index has not closed below the 6,800 mark since 22 August when it settled at

Read more
8 Sep 2014 11:20

Glaxo Presents Data From Blood Eosinophil Levels Studies

Read more
8 Sep 2014 10:36

BUZZ-U.S. Stocks on the Move-Keryx, GlaxoSmithKline, Astrazeneca

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for more market insights, including options activity, ; for the Day Ahead newsletter, http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) U.S. stock

Read more
8 Sep 2014 08:35

UK BROKER RATINGS: Bernstein Raises Tesco And Cuts Morrisons

Read more
8 Sep 2014 06:55

AstraZeneca drug misses goal in severe COPD but improves lung function

LONDON, Sept 8 (Reuters) - An experimental drug from AstraZeneca - part of a new wave of injectable respiratory drugs designed for people who do not respond adequately to traditional inhalers - has shown mixed results in chronic lung disease. Data published in The Lancet on Monday and being

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.